Post progression survival in glioblastoma: where are we?

Enrico Franceschi; Mario Ermani; Stefania Bartolini; Marco Bartolotti; Rosalba Poggi; Giovanni Tallini; Gianluca Marucci; Antonio Fioravanti; Alicia Tosoni; Raffaele Agati; Antonella Bacci; Eugenio Pozzati; Luca Morandi; Damiano Balestrini; Claudio Ghimenton; Girolamo Crisi; Alba A. Brandes

doi:10.1007/s11060-014-1651-7

Post progression survival in glioblastoma: where are we?

Enrico Franceschi, Mario Ermani, Stefania Bartolini, Marco Bartolotti, Rosalba Poggi, Giovanni Tallini, Gianluca Marucci, Antonio Fioravanti, Alicia Tosoni, Raffaele Agati, Antonella Bacci, Eugenio Pozzati, Luca Morandi, Damiano Balestrini, Claudio Ghimenton, Girolamo Crisi, Alba A. Brandes

Istituto Scienze Neurologiche

Research output: Contribution to journal › Article › peer-review

Abstract

The optimal end point for phase II studies for recurrent glioblastoma (GBM) is unclear and a matter of debate. Moreover, data about post-progression survival (PPS) after the first disease progression in GBM patients treated according to EORTC 26981/22981/NCIC CE.3 trial are limited. The aim of this study was to evaluate the PPS in GBM patients. The analysis was made with a database on 1,006 GBM patients followed prospectively between 06/2005 and 06/2010. Eligibility criteria for the study were: age ≥18 years; PS: 0–2; chemotherapy given at disease progression after RT/TMZ. 232 patients (mean age 52 years, range 18–77 years) were enrolled. The median PFS following second line chemotherapy (PFS2) was 2.5 months (95 % CI 2.1–2.9) and the rate of patients free of progression at 6 months (PFS2-6 mo), was 21.6 % (95 % CI 16.3–26.9 %). The median PPS was 8.6 months (95 % CI 7.4–9.8), PPS rates were: PPS-6: 66 % (95 % CI 60.3–72.9 %), PPS-9: 48.2 % (95 % CI 41.5–54.9 %) and PPS-12: 31.7 % (95 % CI 25.2–38.2 %). PPS in unselected patients treated with alkylating agents is about 8 months. PPS rates could be of interest as an end point in future studies in recurrent GBM.

Original language	English
Pages (from-to)	399-404
Number of pages	6
Journal	Journal of Neuro-Oncology
Volume	121
Issue number	2
DOIs	https://doi.org/10.1007/s11060-014-1651-7
Publication status	Published - 2014

Keywords

End points
Glioblastoma
Post-progression survival
Progression-free survival
Recurrence

ASJC Scopus subject areas

Clinical Neurology
Cancer Research
Oncology
Neurology
Medicine(all)

Access to Document

10.1007/s11060-014-1651-7

Cite this

Franceschi, E., Ermani, M., Bartolini, S., Bartolotti, M., Poggi, R., Tallini, G., Marucci, G., Fioravanti, A., Tosoni, A., Agati, R., Bacci, A., Pozzati, E., Morandi, L., Balestrini, D., Ghimenton, C., Crisi, G., & Brandes, A. A. (2014). Post progression survival in glioblastoma: where are we? Journal of Neuro-Oncology, 121(2), 399-404. https://doi.org/10.1007/s11060-014-1651-7

Franceschi, E, Ermani, M, Bartolini, S, Bartolotti, M, Poggi, R, Tallini, G, Marucci, G, Fioravanti, A, Tosoni, A, Agati, R, Bacci, A, Pozzati, E, Morandi, L, Balestrini, D, Ghimenton, C, Crisi, G & Brandes, AA 2014, 'Post progression survival in glioblastoma: where are we?', Journal of Neuro-Oncology, vol. 121, no. 2, pp. 399-404. https://doi.org/10.1007/s11060-014-1651-7

@article{00922188f77144d095b3241a2d38c9b5,

title = "Post progression survival in glioblastoma: where are we?",

abstract = "The optimal end point for phase II studies for recurrent glioblastoma (GBM) is unclear and a matter of debate. Moreover, data about post-progression survival (PPS) after the first disease progression in GBM patients treated according to EORTC 26981/22981/NCIC CE.3 trial are limited. The aim of this study was to evaluate the PPS in GBM patients. The analysis was made with a database on 1,006 GBM patients followed prospectively between 06/2005 and 06/2010. Eligibility criteria for the study were: age ≥18 years; PS: 0–2; chemotherapy given at disease progression after RT/TMZ. 232 patients (mean age 52 years, range 18–77 years) were enrolled. The median PFS following second line chemotherapy (PFS2) was 2.5 months (95 % CI 2.1–2.9) and the rate of patients free of progression at 6 months (PFS2-6 mo), was 21.6 % (95 % CI 16.3–26.9 %). The median PPS was 8.6 months (95 % CI 7.4–9.8), PPS rates were: PPS-6: 66 % (95 % CI 60.3–72.9 %), PPS-9: 48.2 % (95 % CI 41.5–54.9 %) and PPS-12: 31.7 % (95 % CI 25.2–38.2 %). PPS in unselected patients treated with alkylating agents is about 8 months. PPS rates could be of interest as an end point in future studies in recurrent GBM.",

keywords = "End points, Glioblastoma, Post-progression survival, Progression-free survival, Recurrence",

author = "Enrico Franceschi and Mario Ermani and Stefania Bartolini and Marco Bartolotti and Rosalba Poggi and Giovanni Tallini and Gianluca Marucci and Antonio Fioravanti and Alicia Tosoni and Raffaele Agati and Antonella Bacci and Eugenio Pozzati and Luca Morandi and Damiano Balestrini and Claudio Ghimenton and Girolamo Crisi and Brandes, {Alba A.}",

year = "2014",

doi = "10.1007/s11060-014-1651-7",

language = "English",

volume = "121",

pages = "399--404",

journal = "Journal of Neuro-Oncology",

issn = "0167-594X",

publisher = "Springer New York LLC",

number = "2",

}

TY - JOUR

T1 - Post progression survival in glioblastoma

T2 - where are we?

AU - Franceschi, Enrico

AU - Ermani, Mario

AU - Bartolini, Stefania

AU - Bartolotti, Marco

AU - Poggi, Rosalba

AU - Tallini, Giovanni

AU - Marucci, Gianluca

AU - Fioravanti, Antonio

AU - Tosoni, Alicia

AU - Agati, Raffaele

AU - Bacci, Antonella

AU - Pozzati, Eugenio

AU - Morandi, Luca

AU - Balestrini, Damiano

AU - Ghimenton, Claudio

AU - Crisi, Girolamo

AU - Brandes, Alba A.

PY - 2014

Y1 - 2014

N2 - The optimal end point for phase II studies for recurrent glioblastoma (GBM) is unclear and a matter of debate. Moreover, data about post-progression survival (PPS) after the first disease progression in GBM patients treated according to EORTC 26981/22981/NCIC CE.3 trial are limited. The aim of this study was to evaluate the PPS in GBM patients. The analysis was made with a database on 1,006 GBM patients followed prospectively between 06/2005 and 06/2010. Eligibility criteria for the study were: age ≥18 years; PS: 0–2; chemotherapy given at disease progression after RT/TMZ. 232 patients (mean age 52 years, range 18–77 years) were enrolled. The median PFS following second line chemotherapy (PFS2) was 2.5 months (95 % CI 2.1–2.9) and the rate of patients free of progression at 6 months (PFS2-6 mo), was 21.6 % (95 % CI 16.3–26.9 %). The median PPS was 8.6 months (95 % CI 7.4–9.8), PPS rates were: PPS-6: 66 % (95 % CI 60.3–72.9 %), PPS-9: 48.2 % (95 % CI 41.5–54.9 %) and PPS-12: 31.7 % (95 % CI 25.2–38.2 %). PPS in unselected patients treated with alkylating agents is about 8 months. PPS rates could be of interest as an end point in future studies in recurrent GBM.

AB - The optimal end point for phase II studies for recurrent glioblastoma (GBM) is unclear and a matter of debate. Moreover, data about post-progression survival (PPS) after the first disease progression in GBM patients treated according to EORTC 26981/22981/NCIC CE.3 trial are limited. The aim of this study was to evaluate the PPS in GBM patients. The analysis was made with a database on 1,006 GBM patients followed prospectively between 06/2005 and 06/2010. Eligibility criteria for the study were: age ≥18 years; PS: 0–2; chemotherapy given at disease progression after RT/TMZ. 232 patients (mean age 52 years, range 18–77 years) were enrolled. The median PFS following second line chemotherapy (PFS2) was 2.5 months (95 % CI 2.1–2.9) and the rate of patients free of progression at 6 months (PFS2-6 mo), was 21.6 % (95 % CI 16.3–26.9 %). The median PPS was 8.6 months (95 % CI 7.4–9.8), PPS rates were: PPS-6: 66 % (95 % CI 60.3–72.9 %), PPS-9: 48.2 % (95 % CI 41.5–54.9 %) and PPS-12: 31.7 % (95 % CI 25.2–38.2 %). PPS in unselected patients treated with alkylating agents is about 8 months. PPS rates could be of interest as an end point in future studies in recurrent GBM.

KW - End points

KW - Glioblastoma

KW - Post-progression survival

KW - Progression-free survival

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=84925537605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925537605&partnerID=8YFLogxK

U2 - 10.1007/s11060-014-1651-7

DO - 10.1007/s11060-014-1651-7

M3 - Article

C2 - 25366365

AN - SCOPUS:84925537605

VL - 121

SP - 399

EP - 404

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -

Post progression survival in glioblastoma: where are we?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this